Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with
schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000
subcutaneous (SC) injections in subjects with schizophrenia and to continue collecting
clinical outcome data with RBP-7000 SC injections in subjects with schizophrenia using the
Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity Illness
(CGI-S) scale.